Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 312

Posts Tagged ‘collaboration’

Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

Posted by fidest press agency su lunedì, 13 gennaio 2020

Almirall, S.A. (ALM), and WuXi Biologics (“WuXi Bio”) (2269 .HK) have today announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatology diseases including atopic dermatitis.Under the terms of the agreement, Almirall has access to WuXi Biologics’ proprietary antibody platforms including WuXiBody™ to discover multiple novel bispecific antibodies. This strategic collaboration permits Almirall to develop the medication under licence and maintain ownership for medical use of the resulting components to complete the company’s objective of developing biologics to tackle skin diseases.Bhushan Hardas, MD, MBA, Chief Scientific Officer of Almirall, commented that, “This agreement is a big step forward for us in our objective in becoming a leader in biologic medical dermatology treatments. With WuXi Biologics technology platform and our long experience and understanding in the area of dermatology, we will be able to identify new molecules with the potential to become optimal alternative therapies for patients with atopic dermatology”. Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, stated, “We are delighted to establish this collaboration with Almirall, the 12th global partnership since we launched this exciting platform in August 2018. This represents one further step in validating the power and versatile applications of WuXiBody™ in multiple therapeutic areas, underlining our leadership in next-generation biologic technologies and demonstrating our contributions to enable global partners to develop more new treatments for patients worldwide. WuXi Biologics is committed to developing globally leading technologies to accelerate and transform biologics discovery, development and manufacturing”.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Strategic Collaboration Agreement with Amazon Web Services

Posted by fidest press agency su venerdì, 1 novembre 2019

Tyler Technologies, Inc. (NYSE: TYL) today announced a strategic collaboration agreement with Amazon Web Services (AWS) for cloud hosting services. This agreement brings together Tyler, the nation’s largest software company exclusively focused on the public sector, and AWS, the broadest and deepest cloud platform.The agreement deepens the existing relationship between Tyler and AWS, by leveraging the AWS cloud to lay the groundwork for the future of cloud services for the public sector. As Tyler continues to evolve its applications in response to government and public sector needs, this collaboration will enable Tyler public sector clients to deliver better experiences for citizens, and further enable governments to use data as a strategic asset in the design, management, and delivery of programs.
Specifically, the agreement with AWS provides the framework for development, training and collaboration in order to support next-generation applications that have the scalability, resiliency, and security AWS offers. It will assist Tyler in accelerating innovation and the development of strategic initiatives. These initiatives will bring the most advanced cloud-native services to Tyler clients, improving the flow of information and providing a better experience for state, local, and federal governments.The agreement allows Tyler to expand its solution development and delivery options while continuing to support clients, where required, on premises or through another Tyler data center.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Avacta Group plc Enters Collaboration and Option Agreement With ADC Therapeutics

Posted by fidest press agency su sabato, 12 ottobre 2019

Avacta Group plc (AIM: AVCT), a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer® platform, today announced that it has entered a collaboration and option agreement with ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody-drug conjugates for patients suffering from haematological malignancies and solid tumours. The agreement is to develop Affimer-drug conjugates combining Avacta’s Affimer technology with ADC Therapeutics’ pyrrolobenzodiazepine (PBD)-based warhead and linker technologies.As part of the multi-target collaboration Avacta will generate and optimise Affimer binders against three undisclosed cancer targets and provide these to ADC Therapeutics to target its proprietary cytotoxic warheads (PBDs) to the site of the tumour. ADC Therapeutics will carry out pre-clinical research and development programmes to evaluate each of the Affimer-drug conjugates with a view to generating clinical candidates.The commercial agreement between the two companies provides ADC Therapeutics with options, on a target by target basis, to obtain exclusive licenses to the Affimer proteins for clinical development and commercialisation.Under the terms of the agreement, ADC Therapeutics will cover all Avacta’s costs during the collaboration. Upon ADC Therapeutics entering into each of the commercialisation licenses and successfully bringing new Affimer-drug conjugates to market, Avacta will receive option fees, development and commercialisation milestones, as well as a single-digit royalty on sales. Further financial details are not disclosed.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Collaboration Aims to Discover New Immuno-oncology Targets

Posted by fidest press agency su mercoledì, 14 agosto 2019

Harvard University and Merck are launching a collaboration that will provide significant research funding for up to four years to support immuno-oncology research led by Arlene Sharpe, MD, PhD, at Harvard Medical School (HMS). Sharpe, the George Fabyan Professor of Comparative Pathology and chair of the HMS Department of Immunology, will collaborate with researchers at Merck on a major project aiming to discover novel aspects of the immune system that may be targeted in future treatments for cancer.“This collaborative project aims to discover and validate novel regulators of immune responses,” said Dr. Sharpe. “Immunotherapies such as checkpoint inhibitors have revolutionized the treatment of cancer, but my lab is deeply interested in understanding why some patients do not respond or develop resistance to those interventions. My hope is that by defining mechanisms that inhibit immune responses to tumors, we will identify very important druggable targets and new approaches to improve cancer immunotherapy.”The funding will support the work of scientists in the lab of Dr. Sharpe, who is a renowned leader in the field of tumor immunology. She is a member of the National Academy of Sciences and the National Academy of Medicine, and the recipient of numerous awards including the Warren Alpert Foundation Prize in 2017 for her contributions to the discovery of the PD-1 pathway.Under the agreement spearheaded by Harvard’s Office of Technology Development, Merck will have the option to negotiate an exclusive license to innovations arising from the research collaboration to develop these discoveries toward potential treatments for patients.“Collaboration with leading scientific groups is an integral part of Merck’s discovery strategy,” said Dr. Nick Haining, vice president for oncology discovery at Merck Research Laboratories. “We look forward to working with Dr. Sharpe’s team to investigate new ways to harness the immune system for therapeutic advances.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Ford – Volkswagen expand their global collaboration to advance autonomous driving, electrification and better serve customers

Posted by fidest press agency su lunedì, 15 luglio 2019

Ford Motor Company and Volkswagen AG today announced they are expanding their global alliance to include electric vehicles – and will collaborate with Argo AI to introduce autonomous vehicle technology in the U.S. and Europe – positioning both companies to better serve customers while improving their competitiveness and cost and capital efficiencies. Volkswagen CEO Dr. Herbert Diess, Ford President and CEO Jim Hackett as well as Argo AI CEO Bryan Salesky announced Volkswagen is joining Ford in investing in Argo AI, the autonomous vehicle technology platform company.Working together with Ford and Volkswagen, Argo AI’s self-driving system (SDS) is the first with commercial deployment plans for Europe and the U.S. Plus, being able to tap into both automakers’ global reach, Argo AI’s platform has the largest geographic deployment potential of any autonomous driving technology to date. Volkswagen and Ford independently will integrate Argo AI’s SDS into purpose-built vehicles to support the distinct people and goods movement initiatives of both companies.Argo AI’s focus remains on delivering a SAE Level 4-capable SDS to be applied for ride sharing and goods delivery services in dense urban areas.Ford and Volkswagen will have an equal stake in Argo AI, and combined, Volkswagen and Ford will own a substantial majority. The remainder will be used as an incentive pool for Argo AI employees. The full transaction is subject to regulatory approvals and closing conditions.
Company leaders also announced Ford will become the first additional automaker to use Volkswagen’s dedicated electric vehicle architecture and Modular Electric Toolkit – or MEB – to deliver a high-volume zero-emission vehicle in Europe starting in 2023.Ford expects to deliver more than 600,000 European vehicles using the MEB architecture over six years, with a second all-new Ford model for European customers under discussion. This supports Ford’s European strategy, which involves continuing to play on its strengths – including commercial vehicles, compelling crossovers and imported iconic vehicles such as Mustang and Explorer. Volkswagen started developing its MEB architecture in 2016, investing approximately $7 billion in this platform. The car-maker is planning to use this platform to build approximately 15 million cars for the Volkswagen Group alone in the next decade.
For Ford, using Volkswagen’s MEB architecture is part of its more than $11.5 billion investment in electric vehicles worldwide – and supports Ford’s commitment to offer its European customers a broad range of electric vehicles while meeting its sustainability commitments.The companies also are on track to deliver medium pickup trucks for global customers, aiming to start in 2022, followed by commercial vans.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The collaboration of six Nordic banks results in a joint KYC company

Posted by fidest press agency su domenica, 7 luglio 2019

Stockholm. Danske Bank A/S, DNB Bank ASA, Nordea Bank Abp, Skandinaviska Enskilda Banken AB (publ), Svenska Handelsbanken AB (publ) and Swedbank AB (publ) are moving forward and have established a joint venture company to develop a platform for handling KYC (Know Your Customer) data. The European Commission has given its approval in accordance with the EU merger control rules.The joint venture company is preparing for its first commercial launch in 2020. The company is autonomous and will initially offer KYC services to the market concerning large and medium-sized companies based in the Nordic region.“The collaboration between all banks has been both effective and successful. Together, we have in a short period of time worked on a Nordic KYC utility standard for compliant KYC information and explored alternatives for a future digital solution. As we have now received the green light from the European Commission, we are ready to move forward with our plans,” says Fredrik Millde, interim CEO of the Nordic KYC utility.The banks’ top priority in collaborating has been to develop a Nordic platform with standardised processes for handling KYC data. The objective is to improve customer experience by simplifying the KYC processes for corporate customers while strengthening financial crime prevention in the Nordics.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Almirall announced that a key milestone under the collaboration with Nuevolution has been achieved

Posted by fidest press agency su lunedì, 4 marzo 2019

The strategic collaboration was entered on December 12, 2016 with the aim to develop innovative RORγt inhibitors with best-in-class potential for the oral and topical treatment of Dermatology diseases and Psoriatic Arthritis.A significant part of the collaboration work has been to evaluate preclinical safety parameters of RORγt inhibition and to comprehensively de-risk the program prior to any human testing. The milestone data achieved supports a program with a Candidate Drug (CD) having best-in-class potential.The program continues its progression towards clinical development. The positive result triggered a contractual milestone to Nuevolution.Bhushan Hardas, M.D., MBA, Chief Scientific Officer of Almirall, commented “we are very pleased with the progress achieved in our strategic collaboration with Nuevolution, which reflects Almirall’s commitment to becoming a leader in medical dermatology by reinforcing our pipeline with true innovative best in class solutions”.Alex H. Gouliaev, Ph.D., Chief Executive Officer of Nuevolution, commented: “this underscores the positive opportunities for this very unique program. The program development has benefitted significantly from much synergy between and dedication by the teams”.Almirall had one of the highest levels of R&D investments in the Spanish Pharmaceutical Industry in 2018, representing over 12% of Net Sales (€88 MM). In addition, Almirall invests in assets, strategic partnerships and collaborations in research. For more information, please visit almirall.com

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases

Posted by fidest press agency su venerdì, 21 dicembre 2018

Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases.Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be responsible for the program’s preclinical and clinical development and commercialization. Scholar Rock retains exclusive worldwide rights to discover, develop, and commercialize certain TGFβ inhibitors for oncology and cancer immunotherapy.In connection with the collaboration agreement, Scholar Rock will receive $80 million in upfront payments, comprised of $50 million cash and $30 million purchase of Scholar Rock Holding Corporation common stock. In addition, Scholar Rock will receive a one-time milestone payment of $25 million upon the successful completion of specific preclinical studies and be eligible to receive up to an additional $1,425 million in potential payments aggregated across all three programs based on the successful achievement of certain research, development, regulatory and commercialization milestones. Scholar Rock would also receive high single-digit to low double-digit tiered royalties on sales of potential future products originating from the collaboration.
Fibrosis is a debilitating pathological feature of many diseases that scars tissues and vital organs and is a major cause of morbidity and mortality. TGFβ-driven signaling is thought to be a central regulator of fibrosis. Inhibitors of TGFβ signaling discovered through Scholar Rock’s proprietary platform have been shown to selectively prevent the activation of the growth factor in the fibrotic matrix in vitro and in preclinical models. By targeting the disease microenvironment, these highly specific inhibitors of TGFβ activation may offer a novel approach to suppressing pro-fibrotic signaling in multiple organs.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Collaboration Among National Ecological Observatory Network (NEON) and United States Geological Survey

Posted by fidest press agency su domenica, 11 novembre 2018

By any measure, the Wind River Experimental Forest is a remote area. Yet two teams of ecologists managed to meet up and collaborate in their efforts to study the federally threatened Steelhead Trout species (Oncorhynchus mykiss) and map the long-term overall health of the aquatic system.The United States Geological Survey (USGS) is a fact-finding research organization that has scientists studying the landscape across the country including its natural resources and the natural hazards that threaten it. For decades, its Columbia River Research Laboratory (a field station of USGS Western Fisheries Research Center) has worked in the Wind River watershed to monitor the health of salmonids and steelhead populations, their response to human activities, and the factors limiting their abundance. The lab works in close coordination with other agencies in the Wind River watershed including the U.S. Fish and Wildlife Service, the Washington Department of Fish and Wildlife (WDFW), and the U.S. Forest Service. Funding for much of the work is provided by the Bonneville Power Administration.
The NEON project, managed by Battelle for the National Science Foundation, is a continental-scale ecological observation facility that collects and provides open data from 81 field sites across the United States that characterize and quantify how our nation’s ecosystems are changing. The data will contribute to a better understanding and more accurate forecasting of how human activities impact ecosystems and how society can more effectively address critical ecological questions and issues.Martha Creek, a tributary to the Wind River, hosts a NEON study reach that is slated to remain active for the full 30-year duration of the project. NEON’s presence in Martha Creek has been in the works for years, and sampling finally began in November 2017. Through it all, USGS staff have been supportive stakeholders. For example, Ian Jezorek, a fish biologist who has been studying the steelhead population for years, provided training opportunities to NEON field ecologists in fish identification and recognition of redds, the nesting areas of steelhead and other salmonids. As a source of open data on stream and environmental conditions, fish populations, and more, NEON’s Martha Creek site now produces a rich dataset that complements the USGS and other Wind River partners’ efforts.Once NEON had the Martha Creek field site up and running, the scientists realized they had an opportunity to be more efficient with their fish sampling goals by coordinating efforts. A primary study method for USGS and WDFW is tagging of juvenile and adult Steelhead with Passive Integrated Transponder (PIT) tags. These very small tags are uniquely coded and can allow researchers to follow movements and growth of individual fish through their lifespan. Detection and recapture sites in the Wind River watershed and throughout the Columbia River provide the ability to gather complete life histories of detected fish.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Collaboration with Indiana University School of Medicine

Posted by fidest press agency su domenica, 28 ottobre 2018

Cook Regentec, Cook Group’s first company in Indianapolis, cut the ribbon Wednesday on its new facility on Indiana Avenue and announced a collaboration with Indiana University School of Medicine aimed at developing tools and technologies that advance solutions in the emerging areas of immunotherapy, precision medicine, drug delivery, regenerative medicine and bioprinting. Cook Regentec develops and commercializes research and clinical tools to advance regenerative medicine therapies. The company celebrated the completion of the transformation and rehabilitation of a former beer warehouse into a 22,000-square-foot innovation center with modern, collaborative office space and adjacent advanced laboratory facilities.
Founded in 2015 as an incubator/accelerator for biological and device innovations, Cook Regentec has created three early stage companies that have already commercialized 12 different products, including cellular growth media, solutions for cryopreservation and medical devices for the delivery of therapeutic agents.The relationship with Indiana University School of Medicine delivers on Cook Regentec’s mission to leverage the Indianapolis life sciences and advanced industry ecosystem to continue developing and commercializing new technologies across industries and disciplines. Cook Regentec scientists, engineers and product developers will connect with Indiana University School of Medicine researchers and scientists at The Collaboratory @ Cook Regentec. The new collaboration space is a 6,000-square-foot idea lab and collaborative technology incubator located at Cook Regentec’s newly rehabilitated Indianapolis headquarters.The teams will address unmet needs in the fields of cell and gene therapy and regenerative medicine. Research scientists, clinicians and biopharma companies worldwide use revolutionary cell and gene therapy approaches to uncover new and improved treatments for patients. Cook Regentec works alongside them to develop tools and technologies to address the specialized production, storage and delivery requirements of living cellular medicines.
Cook Regentec has a proven record for the development and commercialization of emerging technologies and Indiana University School of Medicine has a long history of developing and testing new therapies for patients. In recent years the school has made aggressive investments in faculty expertise, infrastructure and technology necessary to make research breakthroughs in the emerging fields of cell and gene therapy through the IU Precision Health Initiative and with the establishment of its new Indiana Center for Regenerative Medicine and Engineering and Brown Center for Immunotherapy.Cook Regentec and Indiana University School of Medicine will be the first collaboration team to use The Collaboratory @ Cook Regentec innovation space and plan to jointly focus on a number of key areas in need of enabling technologies. Initial collaborative projects may include battlefield and trauma applications of bioprocessing tools, targeted delivery of advanced biologic medicines, advanced bioprocessing technologies and molecular tools for the production of engineered cell lines and novel bioprinting applications.
The collaboration with Indiana University School of Medicine represents the type of connections Cook Regentec envisioned when it chose Indianapolis for its newest venture. Its employees are within walking distance of central Indiana’s core research assets, including the medical school and its Indiana Center for Regenerative Medicine and Engineering, the Indiana Biosciences Research Institute, and the 16 Tech Innovation District.

Posted in Estero/world news, Università/University | Contrassegnato da tag: , , | Leave a Comment »

Award-Winning Healthcare System Installs Carestream’s Clinical Collaboration Platform to Enhance Its Image Management Workflow

Posted by fidest press agency su giovedì, 8 febbraio 2018

CARESTREAMDickinson County Healthcare System (Iron Mountain, Mich.) — a recipient of multiple healthcare quality awards — implemented Carestream Health’s Clinical Collaboration Platform (see video link) that features enterprise imaging, vendor-neutral archiving and Vue Motion enterprise viewer module. The Dickinson County system includes a community hospital and five satellite clinics.
“After evaluating several different PACS systems we selected Carestream because its fully featured platform is easy to use and offers the ability to read all modalities from a single workstation,” said Sherry Koepp, the healthcare system’s Manager of Imaging Services.The hospital’s Clinical Collaboration Platform supports lesion management, 3D tools, breast tomography, cardiac CT, breast MR and post processing. It also allows radiologists to read multiple modalities from a single workstation. The radiologists’ reading worklist is color coded so they can easily prioritize STAT reads over high priority or routine exams.Carestream’s advanced features are part of a unified platform that includes vendor-neutral archiving (VNA). “Our original plan was to purchase a separate VNA but our Carestream healthcare IT specialist recommended that we expand our storage area network with Carestream’s VNA software. This significantly reduces our cost without any sacrifice in performance or security,” Ms. Koepp explains.Both radiologists and physicians benefit from the platform’s critical results notification capabilities. “Radiologists can contact physicians to discuss critical results and answer any questions, which is an important factor in optimizing patient care,” reports David Alexa, the healthcare system’s PACS Administrator. The hospital also implemented Carestream’s Vue Motion enterprise viewer, which offers convenient access to patients’ images, videos, waveforms and reports from FDA-approved mobile devices.“Our referring physicians appreciate the ability to view the report and key images on mobile devices. Our ENT, orthopaedic, pulmonary and other specialists use the viewer to aid in diagnosis and treatment for patients,” said Mr. Alexa.System administrators use Carestream’s Vue Beyond to improve departmental workflow. This platform provides real-time monitoring of metrics that include study volume, modality mix, patient type and report turnaround time.Carestream’s Clinical Collaboration Platform delivers standards-based data capture, management, archiving and distribution for imaging data across the healthcare enterprise. The platform’s unified core is the backbone that enables enterprise imaging and associates all data for each patient with a single patient record. This imaging data can be easily integrated within a healthcare facility’s EMR/EHR. (photo: CARESTREAM)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

eCurrency Announces Collaboration with ITU on Standardization Guidelines

Posted by fidest press agency su mercoledì, 15 novembre 2017

Beijinge. BeijingCurrency Mint Limited (eCurrency) announced today that it is contributing its seven-layer security architecture to an International Telecommunication Union (ITU) working group’s development of a reference architecture for digital fiat currency (DFC). This working group is tasked with outlining the framework for DFC, showing interoperability scenarios and integration into current payments systems.The working group was established at the first meeting of the ITU Focus Group on Digital Currency including Digital Fiat Currency (FG DFC) held at the Chinese Academy of Social Sciences in Beijing, 12-13 October 2017. The meeting was jointly hosted by ITU, the People’s Bank of China (PBOC), the Information and Communication Ministry, and the Digital Fiat Currency Institute.“The first meeting of the Focus Group welcomed broad, enthusiastic support from both the public and private sectors,” said Bilel Jamoussi, chief of the ITU-T Study Groups Department. “We are in a strong position to encourage digital currency innovation with the support of all stakeholders, stakeholders that will come together in this Focus Group to build a common understanding of their respective roles in managing ICT-driven transformations of the financial system.” The work of the FG DFC leverages the collaboration of all players in the ecosystem including Central Banks and financial standards bodies. The group has been created to establish guidelines for policy and regulation, study the impact on business and technology, and propose a reference architecture to ensure security.In his keynote speech, Yao Qian, director of the PBOC’s Institute of Digital Money, defined DFC by four fundamental properties as follows (paraphrased and translated): “DFC is defined by (1) its value, which is anchored by the trust of the nation as the unit of account, (2) its cryptography, forming its technology base, its algorithms, which are based on big data and artificial intelligence, and (4) its applications, which allow user experience and economic policies to be smarter.”DFC is authorized and issued by a country’s Central Bank as legal tender, designed to offer the same security status and interoperable function as physical currency. It uses high-security cryptographic protocols to ensure that it cannot be counterfeited, while remaining fully transparent. This secure instrument can be held in all e-money wallets and transacted seamlessly within existing network infrastructure.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Rag & Bone Announces New Collaboration with Disney and Lucasfilm

Posted by fidest press agency su mercoledì, 8 novembre 2017

Disney1The capsule collection will offer a selection of iconic rag & bone styles twisted with timeless Star Wars references. Contrasting colorways and hidden details represent the balance between good and evil in the saga depicting the two sides of the Force – the light side and the dark side, the opposing factions of the Galactic Empire and Rebel Alliance, or the conflict between the Resistance and the First Order.
On the collection, rag & bone’s Chief Executive Marcus Wainwright said, “I have always been a huge fan of Star Wars and it has been awesome to create a collection which coincides not only with the launch of Star Wars: The Last Jedi, but also with the 40th anniversary of the franchise. Our approach was really to re-imagine some of our favorite rag & bone pieces while taking influence from some of our most memorable moments of past and present Star Wars films.” The special edition apparel and accessories styles range from $95-$1295; due to be released in batches in select rag & bone stores, on http://www.rag-bone.com and select pieces will also be available on the newly relaunched ShopDisney.com site from December 1, 2017.Wainwright continues: “We wanted the pieces to feel like something that referenced Star Wars but that also fit the rag & bone aesthetic—like a real-word Jedi.”In addition to the capsule, rag & bone will support Lucasfilm and Disney’s Force 4 Fashion initiative; a charitable program under the banner Star Wars: Force for Change that was created to empower and improve the lives of children around the world. rag & bone will make a donation to Starlight Children’s Foundation, continuing Lucasfilm’s philanthropic message of encouraging fans to be forces of change in their community.
rag & bone also announces the launch of the rag & bone | Star Wars secret site which will give viewers access to content created to celebrate the collaboration; including a “making of” video and other footage and images from the world of Star Wars, which this year celebrates its 40th anniversary.To celebrate the launch of the rag & bone | Star Wars collaboration, rag & bone, Lucasfilm and Disney will host three events on December 2nd in New York, Los Angeles, and London featuring surprise elements from the Star Wars franchise. Fans will also have the chance to purchase the limited edition t-shirts with a new t-shirt landing in stores and online each day beginning December 1st through December 4th.

Posted in Economia/Economy/finance/business/technology, Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Ethris Enters Strategic Collaboration with AstraZeneca and MedImmune

Posted by fidest press agency su giovedì, 24 agosto 2017

polmoniEthris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilised non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM®RNA technology. Ethris will receive €25 million upfront plus research funding and is eligible for future research and development milestones, including sales related royalties upon commercialisation. AstraZeneca and MedImmune will have the option to take exclusive worldwide licenses upon completion of the research plan for each target within the collaboration.mRNA therapies deliver genetic instructions to cells which drive the target cells to produce selected proteins to help prevent or fight diseases. Ethris’ proprietary mRNA technology can be targeted to the lungs where it helps to replace, inhibit or augment proteins that are involved in causing or exacerbating respiratory disease. mRNA-based therapeutics may also provide new opportunities to modify the course of the disease or its symptoms.Ethris will utilize its proprietary SNIM®RNA technology exclusively with AstraZeneca through the company’s MedImmune and Innovative Medicines (IMED) biotech units to develop multiple new targets for investigation in the diseases of asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.Dr. Carsten Rudolph, President and CEO of Ethris, said: “This collaboration validates Ethris’ leading position in development and delivery of mRNA therapies for the treatment of pulmonary diseases. This collaboration pairs our proprietary technology with the world-class expertise of AstraZeneca and MedImmune in respiratory diseases, biologics development and commercialisation, and positions us to bring forward new options for patients.” Bahija Jallal, Executive Vice President, MedImmune, added: “Rapid advances over the last decade have made mRNA a very promising tool for clinical application, and we are excited to collaborate with Ethris, whose advanced platform is leading in RNA delivery to the lung. This collaboration complements our respiratory science focused on early intervention and disease modification by adding novel ways to target disease mechanisms that cannot be addressed by other approaches currently in our pipeline.”

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies

Posted by fidest press agency su mercoledì, 23 agosto 2017

Christopher Hansung KoSamsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis.
“Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” said Christopher Hansung Ko, President and CEO, Samsung Bioepis. “Five years ago, we entered the biopharmaceutical industry with a strong determination to transform the way therapies are brought to patients by replacing legacy processes with new and innovative ones. Together with Takeda, we look forward to realizing this vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option.”
The risk-sharing partnership brings together Samsung Bioepis’ agile biologics development platform with Takeda’s best-in-class experts in drug development to co-fund and collaboratively develop innovative therapies representing meaningful value to patients who need them. Additional terms of the collaboration are not being disclosed.“At Takeda, we think differently – and creatively – about what makes a partnership successful and look to build on our strengths by collaborating with partners who have complementary expertise,” said Daniel Curran, M.D., Head, Center for External Innovation, Takeda. “This collaboration with Samsung Bioepis does that, by combining our unique capabilities in development and manufacturing along with fresh and innovative clinical approaches, we will maximize the potential for successful introduction of important medicines to patients.” (photo: Christopher Hansung Ko)

Posted in Medicina/Medicine/Health/Science, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

PR Almirall and Symatese enter into a global strategic collaboration for the development and commercialization of products in the Aesthetics field

Posted by fidest press agency su venerdì, 17 marzo 2017

barcellonaAlmirall S.A., a global pharmaceutical company based in Barcelona, and Symatese, a leading developer and manufacturer of innovative medical devices with more than 30 years of experience, announced today that they have entered into a global collaboration for the development and commercialization of customized products in the Aesthetics field.In accordance with the terms of this collaboration, Symatese grants Almirall an exclusive license for the commercialization of a new range of Hyaluronic Acid facial fillers worldwide in exchange of an upfront payment of €7.5 Million and subsequent event milestones, royalties and sales milestones. In line with Almirall’s strategy to continue building a presence in the Aesthetic market, this collaboration represents not only an attractive opportunity to enter the injectable facial filler market with a differentiated technology, but also create a long-term partnership with a leading developer of medical devices for aesthetic applications.Activities will first be focused on the development of a new Hyaluronic Acid-based transformation technology. This technology will enable Almirall to provide a new, safe, efficacious and versatile range of dermal facial fillers that will satisfy patient desires to replace lost facial volume with predictable, natural looking and satisfying results.Eduardo Sanchiz, CEO of Almirall, commented: “Following the acquisition of ThermiGen, a leading player in the radiofrequency energy-device market, with this collaboration Almirall continues to make progress with its strategic direction into Dermatology and medical Aesthetics. This long-term partnership with Symatese, a leading developer of medical devices, ensures that Almirall will have access to future innovations for the dermal filler market covering our customers unmet needs.”
The dermal filler market has demonstrated significant growth over the last decade and is expected to reach €2.4 bn in 2022 worldwide. A hyaluronic acid-based filler acts like an inflated cushion to support facial structures and tissues that may have lost volume or elasticity due to the normal aging process. It also brings hydration to the skin to keep it looking fresh and supple. Hyaluronic Acid fillers represent approximately 90% of this market. A Hyaluronic Acid filler range is considered an important base of an aesthetic portfolio, commercially synergistic with other aesthetics products.
Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.
Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2.000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.

Posted in Estero/world news, Spazio aperto/open space | Contrassegnato da tag: , , | Leave a Comment »

How the trend for more collaboration can deliver better performance

Posted by fidest press agency su giovedì, 5 maggio 2016

Companies that build formal collaborations with rivals boost their business performance, new research has found.It had been thought that standardisation of collaborative business relationships would hinder creativity and stymie the whole partnership with bureaucracy and a lack of trust hindering ‘joined-up’ processes. But a study of 107 companies, including 20 interviews with senior executives, by Mehmet Chakkol and Mark Johnson, of Warwick Business SchoolBusiness School, found that it is only through formal and systematic processes that managers understand the benefits of collaboration in terms of cost and business growth.
This formalisation, however, refers to systematic adoption of collaborative working and does not entail strict job descriptions or penalties that counter collaborative behaviour.Dr Chakkol said: “The prior evidence we reviewed had suggested standardising collaboration would not be feasible, because it is such a long-term activity and is very flexible in terms of the day-to-day activities and problem solving.“But when we investigated it further we found that is not true. Collaboration leads to a host of benefits including boosting business performance and this is statistically higher for organisations that have formalised their collaborations through the British Standard for Collaboration (BS11000).“We found companies need and want to know what to expect from a collaboration and they want to know what a good collaboration looks like, especially as they are happening more and more.
“And putting in place a formalised process does bring benefits. Top of the list is improved business and operational performance, for example the collaboration between Lockheed Martin and National Air Traffic Services has ensured that Heathrow has run at 98 per cent capacity for more than a decade thanks to both working hard to optimise their partnership through a standard process.
“Collaboration has also brought more contracts for companies, enhanced risk management, brought innovation, increased client confidence and repeat business, new product development as well as multi-million pound efficiencies.”The study found the increasing amount of global trade, and complex and longer supply chains means companies are more interdependent than ever.
“Customers are pushing suppliers into collaboration rather than competing for contracts as it is more efficient,” says Dr Johnson. “This is something the UK Government is very keen on now, and it is happening across different industries from transportation and construction to healthcare and retail, so finding a tried and trusted method of collaborating through an international standard is something companies are looking for.”Our study found that nearly 80 per cent of companies believe they will be spending more time on collaborations in the future.“We found the most significant future challenge for adopting collaborative working is to change traditional organisational cultures to accept more co-operative business models. This highlights the need to identify and further develop competencies and skills to harness collaborative working both at individual and organisational levels”.

Posted in Estero/world news, Università/University | Contrassegnato da tag: , , | Leave a Comment »

Collaboration between Lloyd’s Register Energy and the Italian Association of Pressure Equipment achieves major step forward to support manufacturers in Italy

Posted by fidest press agency su giovedì, 18 giugno 2015

milanodavedereAnnounced, a new Pressure Vessel Manufacturers Forum (PVMF) will take place on July 3rd in Milan to help drive collaboration and knowledge share for Italian manufacturers.In a drive to unite the interests of Italy’s pressure equipment manufacturers, the goal of the new Pressure Vessel Manufacturer Forum (PVMF) is to bring manufacturers together to share information on manufacturing techniques and trends, and to encourage and generate discussion and debate.It is a new industry group sponsored and organized by Lloyd’s Register Energy and the Italian Association of Pressure Equipment (AIPE) – Associazione italiana Pressure Equipment.“We invite all manufacturers of pressure equipment in Italy to join the PVMF on 3rd July in Milan, which promises to create a positive atmosphere for networking, collaboration and the sharing of knowledge,” says Federico Zanette, Sales and Marketing Representative for Lloyd’s Register Energy in Italy.
Zanette reinforced that the needs of manufacturers across Italy are at the core of this initiative. Its focus on uniting manufacturers will demonstrate to the wider world the importance of how working collectively together for the combined interests of manufacturers, will positively impact Italy’s growing competitive manufacturing sector and its performance long term.Luca Tosto, President of AIPE, says: “We believe PVMF offers one of the most relevant events of the sector and we are very glad that it will be replicated in Italy with Lloyd’s Register Energy’s support.“We expect a high attendance and an active participation of many leading companies – collectively giving every attendee the opportunity to discuss business trends, explore potential markets and new collaborations.”Tosto expects the reaction from the market to be extremely positive and will illustrate Lloyd’s Register Energy’s and AIPE’s ability to provide industry-focused solutions tied to manufacturer’s business objectives.The Italian PVMF event follows a similar model that has been successful in the United Kingdom, also started by Lloyd’s Register Energy. That group has a growing attendance of 17 members and 3 affiliate members spanning Scotland, Wales and England.

Posted in Cronaca/News, Economia/Economy/finance/business/technology | Contrassegnato da tag: , , , | Leave a Comment »

Stronger together: Collaboration at policy level to tackle the allergy epidemic in Europe

Posted by fidest press agency su mercoledì, 10 giugno 2015

barcelonaBarcelona (Spain) Yesterday, allergy experts and EU policy-makers met to discuss actions to be undertaken in partnership at the EU level to help curb the growing allergy epidemic in Europe.Allergy has become an epidemic in the EU: more than 150 million Europeans live with allergy and the current prediction is that by 2025 half of the entire EU population will be affected. Furthermore, allergy imposes a significant social and economic burden on EU citizens and health systems. The avoidable indirect costs of failure to treat allergy properly in the EU is estimated to be between 55 and 151 billion Euro per annum.Representatives from the European Commission, European Parliament, European Medicines Agency, European Patients Advocates, Industry, key EU Health Stakeholders, primary care and pharmacist organisation, EAACI leadership and its national allergy societies agreed during a high-level EU stakeholders meeting in Barcelona to work together at policy level on action which will help tackle this epidemic.Nikos Papadopoulos, immediate Past President of EAACI, opened the meeting stating that prioritisation of allergy on the EU health and environment policy agenda is urgently needed. Success in tackling the allergy crisis in Europe will require partnerships between all interested stakeholders and collaborative actions at EU policy level. Member of the European Parliament (MEP) Sirpa Pietikaïnen, who chairs the new MEP Interest Group on allergy and asthma in the European Parliament said “We need to act now and rally strong political support to take concrete actions.” Pietikaïnen further insisted that a strong EU action plan inclusive of both health and environment issues is of paramount importance.The guest speakers Christine Rolland, Marta Munoz Cuesta, Sergio Bonini and Roberto Gradnik – representing respectively the European Federation of Allergy and Airways Diseases Patients’ Association (EFA), the European Commission (DG Environment), the European Medicines Agency (EMA) and European Biopharmaceutical Enterprises (EBE) – highlighted the main priorities from a patient, policy, scientific and industry perspective.All panellists agreed on the importance to improve the patients’ accessibility to appropriate care. Two of the key steps in that direction would be to formally recognise the allergology medical specialty and ensure adequate allergy training and education for primary care to improve early and accurate diagnosis. The necessity to develop a comprehensive EU strategy on chronic diseases and to foster allergy research in Europe by ensuring allocation of sufficient funding, were also addressed as main priorities.Antonella Muraro – incoming President of EAACI concluded that EAACI is fully committed to working in partnerships at all levels – from science to policy- to address unmet needs of allergy and asthma in Europe. She further announced that the next meeting of the MEP group on Allergy and Asthma – which is jointly coordinated by the EAACI EU Liaison Office in Brussels and EFA – will take place on 1 July at the European Parliament. The meeting entitled ‘Allergy and Asthma Patients need clean air in Europe’ will be a collaborative policy forum to debate current EU efforts to review clean air legislation and to ensure allergy patients’ needs are duly considered by EU policy makers.
The European Academy of Allergy and Clinical Immunology, EAACI, is a non-profit organisation active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 8,500 members from 121 countries, as well as 49 National Allergy Societies.

Posted in Uncategorized | Contrassegnato da tag: , , , | Leave a Comment »

New generation of fundraising thought leaders sought to join think tank’s Advisory Panel

Posted by fidest press agency su martedì, 2 giugno 2015

Plymouth University, Davey buildingPlymouth University’s fundraising think tank, Rogare, has started a round of recruitment to its advisory panel. We are looking for the best new thinkers in fundraising to help us translate our research into professional practice around the world.For the first time, Rogare will be looking to recruit panel members from outside the UK and, as part of the collaboration with the Resource Alliance announced last month, the Resource Alliance will help Rogare identify potential candidates, particularly from the global South. We are also looking for new members from Europe and North America, as well supplementing our UK contingent.Ian MacQuillin, Rogare’s director, says: “We are very keen to develop and promote a new generation of fundraising thought leaders whose voices are possibly not currently heard. We want to achieve a paradigm shift in the way fundraisers use theory and evidence to tackle the challenges confronting their profession. This is an exciting opportunity for fundraises with excellent critical thinking skills to be part of the movement that delivers this change.“We’d intended to internationalise the think tank in 2016, but the level of interest from overseas and the support of the Resource Alliance has been such that we are able to do this a year ahead of schedule.”Laura Boulton, conference and strategy director at the Resource Alliance, says: “No matter where people are in the world it’s important that we hear from them about the critical issues facing the sector. We’re passionate about having global voices in the room because as Rogare produces their findings, translating those learnings across the world will be key. We’re hoping that global voices will offer fresh perspectives on the topics we’re exploring and bring different ways of thinking to the group.”The main role for advisory panel members is to disseminate Rogare’s research and other outputs to key audiences, including fundraising practitioners and other potential users of the research, and identify ways these outputs can be translated into professional practice.Panel members will also help Rogare identify the subject areas we explore through than annual ‘scoping study’, and contribute new thinking and ideas to the Critical Fundraising blog. Using ‘critical fundraising principles’, applicants will be asked to write a 500-word essay that describes what they think is the biggest challenges facing fundraising and what they would do to tackle it.This will be assessed by a selection panel comprising: Ian MacQuillin; Amanda Shepard, the advisory panel’s co-ordinator; Laura Boulton, conference and strategy director of the Resource Alliance; and two other current members of the advisory panel yet to be appointed. The application process is now live and runs until 30 June 2015.

Posted in Estero/world news, Università/University | Contrassegnato da tag: , , , | Leave a Comment »